Latest News and Press Releases

No new clinical data is required to add PH-ILD indication as per FDA correspondenceRecertified that YUTREPIA does not infringe any valid patents listed in the Orange Book for TyvasoPreparing for...

Infringement case now only focused on ‘793 patent, previously found to be invalid by PTAB in IPRFederal Circuit expected to hear appeal of PTAB decision in late 4th quarter 2023 to early 2024If PTAB...

Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizerLiquidia funds $10 million...

MORRISVILLE, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that Mr. Roger Jeffs, Chief Executive Officer, and Mr. Michael Kaseta, Chief...

MORRISVILLE, N.C., May 19, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the Company will present data related to the investigational use...

MORRISVILLE, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the first quarter ended March 31, 2023. The...

MORRISVILLE, N.C., May 02, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer, will provide an update on the company's...

MORRISVILLE, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2023 financial results on Thursday, May 4, 2023. The...

MORRISVILLE, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer, will provide an overview and update on the...

New agreement supersedes the collaboration agreement entered in 2012GSK retains non-exclusive right to use PRINT for pre-clinical research for inhaled deliveryLiquidia can apply PRINT to any inhaled...